Ulrik Nilsson, CEO of Spermosens AB (publ), talks about the product JUNO-Checked System, the company's current collaboration agreement and what the upcoming issue proceeds will be used for.
Who are Spermosens and can you briefly tell us about your business?
Spermosens is a life science company with the goal of improving male fertility diagnostics and treatment by introducing products that enable individualized fertility treatments.
Can you tell us about your product JUNO-Checked System?
The global IVF market was worth $22 billion in 2021. Unfortunately, fewer than one in five treatments are successful today. JUNO-Checked will enable measurement of sperm binding ability and thus improve decision-making when choosing treatment. Improved choices lead to improved results.
What is the biggest difference between you and your competitors?
We manufacture a unique patented product that, for the first time, makes it possible to assess whether a man's sperm can fertilize an egg cell. We therefore have no direct competitors.
What does the market potential look like globally and what does that mean for Spermosens?
Globally, more than 3 million cycles are performed annually. With an average selling price of USD 200 per cassette, the market potential is USD 600 million.
In Sweden alone, 20,000 cycles are performed annually and we estimate that we can be cash flow positive with sales of 8,000 cassettes annually.
What is the latest important milestone that Spermosens has achieved?
Spermosens has successfully completed the production preparation phase for the JUNO-Checked cassette together with FlexMedical Solutions Ltd. The next step will be the delivery of generation 1 of the product for research purposes.
Can you tell us a little more about that and what your collaboration with FlexMedical Solutions looks like?
FlexMedical is one of our selected partners, with whom we have developed our plans going forward. FlexMedical Solutions also offers flexible, high-quality production capacity, with the possibility of scaling up as we grow.
In addition to that collaboration, we also have a collaboration agreement with OIM Sweden AB regarding the production of the JUNO-Checked instrument.
You are currently conducting a rights issue of approximately SEK 24.4 million. Can you tell us what the issue proceeds will be used for?
Especially for product development and to deliver Generation 1 of the JUNO-Checked System to be able to begin sales for research purposes.
2023 has arrived. What are your top priorities and milestones to achieve during the year?
Our top priority is to deliver Generation 1 of the JUNO-Checked System to begin sales for research purposes.
Thanks to Spermosens and Ulrik Nilsson for the interview. We wish the company all the best in the new year. Read more about the company at spermosens.com
Disclaimer: This is an interview conducted on behalf of the company. Impala Nordic does not own any shares in the company. Persons behind Impala Nordic act as guarantors in the company's ongoing rights issue.
